Tag: Pharmaceutical Law

Healthcare

Grant Shoebridge: Intellectual Property & The Pharmaceutical Industry

As a preview to some of the issues that will be discussed in our upcoming 9th Annual Pharmaceutical Law, Reform & Regulation Conference, we spoke with Grant Shoebridge, a Principal with Shelston IP to discuss the current issues surrounding patent law and the pharmaceutical industry. As a Principal with Shelston IP with a decade of…

26 Jul 2016, by test test

Healthcare

The Federal Election, Medicare & You

With the Federal Election being held tomorrow, the issue of Medicare and (by extension) Private Health Insurance has once again been thrown into the spotlight with both the Coalition and Labor promising to keep Medicare public and ensure that our system and ensure that our system is free from privatisation. We spoke to Dr Paul…

1 Jul 2016, by test test

Healthcare

Rare cancers: Measuring success in small doses

Rare cancers "is a term which encompasses both rare and less common cancers. A rare cancer is defined as a type of cancer that has less than 6 incidences per year per 100,000 population. A less common cancer is defined as one that has between 6 and 12 incidences per year per 100,000 population" (Cancer…

10 Feb 2015, by test test

Healthcare

Debating drug pricing, regulation and industry transparency

Pharmaceutical companies, law firms, government departments, associations and consultants convened at the Sydney Harbour Marriott on 29th and 30th May 2014, for the 7th Annual Pharmaceutical Law Conference. Over this jam-packed two-day event, discussion centred on a selection of pivotal issues impacting the industry including pharmaceutical law reforms, Intellectual Property, evaluation of the competitive landscape and industry…

16 Jun 2014, by test test

Healthcare

Pharmaceutical industry slams impact of Commission of Audit

The recently released National Commission of Audit has been met with hostile reception from the healthcare industry, particularly from the pharmaceutical sector, as its recommendations threaten to further complicate an already complex profession. According to a May 1 statement from the Pharmaceutical Society of Australia (PSA), one of the recommendations of the Commission of Audit…

12 May 2014, by test test

Healthcare

Close-Up: Professor John Skerritt

Prof. John Skerritt joined the Australian Therapeutic Goods Administration (TGA) as its National Manager in May 2012.  He is also a member of the Executive of the Australian Department of Health.  TGA is responsible for regulating therapeutic goods including prescription, over the counter and complementary medicines, medical devices, blood and blood products.  Prof. Skerritt is…

30 Apr 2014, by test test